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Abstract: Eugenol is a phytochemical present in different plant products, e.g., clove oil. Traditionally,
it is used against a number of different disorders and it was suggested to have anticancer activity.
In this study, the activity of eugenol was evaluated in a human cervical cancer (HeLa) cell line and
cell proliferation was examined after treatment with various concentrations of eugenol and different
treatment durations. Cytotoxicity was tested using lactate dehydrogenase (LDH) enzyme leakage.
In order to assess eugenol’s potential to act synergistically with chemotherapy and radiotherapy,
cell survival was calculated after eugenol treatment in combination with cisplatin and X-rays. To
elucidate its mechanism of action, caspase-3 activity was analyzed and the expression of various
genes and proteins was checked by RT-PCR and western blot analyses. Eugenol clearly decreased
the proliferation rate and increased LDH release in a concentration- and time-dependent manner.
It showed synergistic effects with cisplatin and X-rays. Eugenol increased caspase-3 activity and
the expression of Bax, cytochrome c (Cyt-c), caspase-3, and caspase-9 and decreased the expression
of B-cell lymphoma (Bcl)-2, cyclooxygenase-2 (Cox-2), and interleukin-1 beta (IL-1β) indicating that
eugenol mainly induced cell death by apoptosis. In conclusion, eugenol showed antiproliferative and
cytotoxic effects via apoptosis and also synergism with cisplatin and ionizing radiation in the human
cervical cancer cell line.
Keywords: eugenol; HeLa cells; cisplatin; radiation; apoptosis
1. Introduction
Current cancer treatments are very efficient drugs, yet these medications result in a number of
serious side effects [1,2]. In the search for novel therapies, one promising approach is the use of natural
compounds that stop, delay, or reverse the initiation and progression of carcinogenesis. Some of these
agents act synergistically with established cytostatic drugs or radiation and thus can be considered
chemo- and/or radio-sensitizers [3,4]. Many previous studies have shown the in vivo and in vitro
cytostatic activity of cloves [5,6]. Eugenol, 4-allyl-2-methoxyphenol, is an aromatic phytochemical
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present as the primary constituent of clove oil (Syzygium aromaticum, Myrtaceae) [7]. In addition to its
use as a food additive and scent in makeup [8], it has been generally utilized as a part of conventional
medications in numerous Asian nations as an antiseptic, pain relieving, or antibacterial agent [9]. In
the United States, clove oil has been advertised as a dental pain-relieving agent and germicide, and is
used in mouthwashes and pharmaceutical drugs, and furthermore as a fixing agent in fragrance-based
agents [10]. Different investigations have shown antiviral effects of eugenol [11] and antiproliferative
effects of eugenol-related compounds [12]. Eugenol showed antioxidant activity at low concentrations;
however, at high concentrations, it enhanced the generation of free radicals acting as a pro-oxidant,
leading to cell death [13]. It was reported that eugenol affected the metabolic profile of normal human
oral cells in vitro and caused cellular damage for hepatocytes isolated from rats [14,15]. Eugenol at high
concentrations was also observed to increase the DNA breaks in normal human fibroblast cells [16].
Studies of eugenol showed its different effects on cancer cells; firstly, cancer prevention action by its
antioxidant effect and secondly, pro-oxidant action that kills cancer cells by affecting several signaling
pathways [17]. Eugenol regulates many molecular targets to mediate its cytotoxic effect as it inhibits
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation, downregulates
prostaglandin synthesis, decreases cyclooxygenase-2 (Cox-2) activity, produces cell cycle arrest in
the S phase, increases the generation of reactive oxygen species (ROS), diminishes B-cell lymphoma
(Bcl)-2 level, and reduces inflammatory cytokine levels, resulting in apoptotic cell death [13,18–22].
Investigations of the impacts of eugenol on different cancer cell lines showed apoptosis induction in
human melanoma G361 cells mediated by increased expression of caspase-3 and caspase-6. Apoptosis
in mast cells was triggered by translocation of p53 to the mitochondria [23]. For human leukemia
cells (HL60), a decrease in the mitochondrial membrane potential following the activation of caspase-3
triggered apoptosis [24]. In human colon cancer HT-29 cells, eugenol increased ROS, while decreasing
thiol levels [25]. Furthermore, eugenol inhibited growth and cyclooxygenase-2 expression, showing an
antiproliferative effect on colon cancer cells (HCT-15 and HT-29) [20]. In a dose-dependent manner,
eugenol also induced apoptosis of human breast cancer MCF-7 cells, accompanied by exhaustion in
glutathione (GSH) and an increase in ROS [26].
The second most common malignancy in women is cervical cancer [27]. Despite the fact that
radiotherapy is a compelling treatment methodology, the pelvis is the most widely recognized site of
failure [28–30]. Surgery, chemotherapy and radiotherapy are well-known options for cervical cancer
treatment [31,32]. Although FDA has endorsed the use of two chemotherapeutic agents (topotecan
and cisplatin) for cervical cancer end stages, serious problems including neutropenia, anemia, and
thrombocytopenia frequently occur [22]. Considering the antiproliferative activity of eugenol, its
anticancer activity and molecular mechanism were evaluated in a cervical cancer cell line hoping
for the development of a promising strategy by its combination with cisplatin or radiotherapy for
cancer treatment. The present study investigates the molecular mechanism of eugenol underlying its
antiproliferative effects on human cervical cancer cells (HeLa cells) and their increase in sensitivity to
common therapies.
2. Results
2.1. Eugenol Cytotoxicity on HeLa Cells
2.1.1. Effect of Eugenol on Survival of HeLa Cells
The proliferation of cells was reduced after treatment with increasing concentrations (50–1000
µM) of eugenol as shown in Figure 1A. The proliferation was expressed as a percentage relative to that
of cells cultured in medium only. We used 350 µM concentration of eugenol for all our subsequent
experiments because it produced the optimal effect of about 66 ± 4% survival after 24 h treatment.
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Figure 1. Eugenol cytotoxicity effect on HeLa cells. (A) Effect of eugenol on the proliferation of HeLa 
cells is concentration- and time-dependent. Proliferation of HeLa cells treated, in triplicate, with 
different concentrations (50, 100, 200, 350, 500, 750, and 1000 µM) of eugenol for different time 
intervals was estimated by CCK-8 and expressed as a percentage relative to that of cells cultured in 
medium only. Data represent mean ± standard deviation (SD). CCK-8, Cell Counting Kit-8. (B) 
Eugenol increases LDH enzyme leakage in HeLa cells in a concentration-dependent manner. HeLa 
cells were treated, in triplicate, with different concentrations (0–1000 µM) of eugenol for 24 h. LDH 
release (cytotoxicity) was expressed as a percent relative to that of 10% Triton X-100-treated cells. 
Data represent mean ± SD. Significant difference was analyzed by one-way ANOVA test, where ** p 
< 0.01 and *** p < 0.001 compared to HeLa cells treated with 0 µM eugenol. LDH, lactate 
dehydrogenase. 
2.1.2. Effect of Eugenol on Lactate Dehydrogenase (LDH) Release from HeLa Cells 
The effect of different concentrations (50–1000 µM) of eugenol on LDH release from HeLa cells 
for 24 h (cytotoxicity) is shown in Figure 1B. LDH release is expressed as a percent relative to that of 
Triton X-100-treated cells. Our results showed that treatment of HeLa cells with increasing 
concentrations of eugenol induced a significant release of LDH from HeLa cells in a dose-dependent 
manner of 38 ± 3% and 94 ± 6% at 350 and 1000 µM, respectively, indicating disruption of the cell 
membrane structure. Eugenol at 350 µM was used for all the subsequent experiments. 
2.2. Effect of Eugenol on Sensitivity of HeLa Cells to Cisplatin 
The use of established anticancer agents in combination with natural products may show 
increased antitumor activity due to sensitization of the cancer cells to the anticancer agents induced 
by the effect of these natural products. This could lead to fewer side effects due to using lower 
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Data represent mean ± standard deviation (SD). CCK-8, Cell Counting Kit-8. (B) Eugenol increases
LDH enzyme leakage in HeLa cells in a concentration-dependent manner. HeLa cells were treated, in
triplicate, with different concentrations (0–1000 µM) of eugenol for 24 h. LDH release (cytotoxicity)
was expressed as a percent relative to that of 10% Triton X-100-treated cells. Data represent mean ±
SD. Significant difference was analyzed by one-way ANOVA test, where ** p < 0.01 and *** p < 0.001
compared to HeLa cells treated with 0 µM eugenol. LDH, lactate dehydrogenase.
2.1.2. Effect of Eugenol on Lactate Dehydrogenase (LDH) Release from HeLa Cells
The effect of different concentrations (50–1000 µM) of eug nol on LDH release from HeLa cells for
24 h (cytotoxicity) is shown in Figure 1B. LDH release is expressed as a percent relative to that of Triton
X-100-treated cells. Our results showed that treatment of HeLa cells with increasing concentrations of
eugenol induced a significant release of LDH from HeLa cells in a dose-dependent manner of 38 ± 3%
and 94 ± 6% at 350 and 1000 µM, respectively, indicating disruption of the cell membrane structure.
Eugenol at 350 µM was used for all the subsequent experiments.
2.2. Effect of Eugenol on Sensitivity of HeLa Cells to Cisplatin
The use of established anticancer agents in combination with natural products may show increased
antitumor activity due to sensitization of the cancer cells to the anticancer agents induced by the
effect of these natural products. This could lead to fewer side effects due to using lower doses. The
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effect of different concentrations (0.5–2.5 µM) of cisplatin alone or in combination with eugenol (350
µM) on HeLa cell viability for 24 h is shown in Figure 2. The survival of cells was expressed as a
percentage relative to that of cells treated with medium only (without cisplatin or eugenol). The results
indicated that the combination of eugenol and cisplatin showed a significant (p < 0.001) decrease in
cell viability at all given concentrations. Eugenol increased significantly the sensitivity of HeLa cells
to cisplatin at all cisplatin concentrations when compared to cells treated with cisplatin alone. These
results support the idea that the combination of these drugs has a higher efficacy than monotherapy
with either cisplatin or eugenol.
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Figure 2. Effect of eugenol on sensitivity of HeLa cells to cisplatin. HeLa cells were treated, in 
triplicate, with different concentrations (0–2.5 µM) of cisplatin alone or in combination with eugenol 
(350 µM) for 24 h. The survival of cells, estimated by CCK-8, was expressed as a percentage relative 
to that of cells treated with medium only (without cisplatin or eugenol). Data represent mean ± SD. 
Significant difference was analyzed by one-way ANOVA test, where *** p < 0.001 compared to cells 
not treated with eugenol. 
2.3. Effect of Eugenol on Sensitivity of HeLa Cells to radiation 
The use of radiotherapy for cancer treatment has many adverse effects on adjacent normal cells. 
The synergistic effect between radiation and natural products such as eugenol is interesting because 
this might lead to the use of lower radiation doses resulting in fewer side effects. The effect of 
eugenol treatment (350 µM) for 6 h and then irradiation with (0, 2, 4, and 6 Gy) X-rays on HeLa cell 
proliferation is shown in Figure 3. The survival of cells after 24 h is expressed as a percentage 
relative to that of non-irradiated cells treated with medium only. The results showed that eugenol 
significantly increased the sensitivity of HeLa cells to irradiation at 4 Gy (p < 0.05) and 6 Gy (p < 0.01), 
while it failed to increase the sensitivity of HeLa cells at 2 Gy irradiation. The survival of cells 
irradiated with only 2, 4, and 6 Gy was 93.1 ± 5.6%, 89.3 ± 4.7% and 70.2 ± 5.1%, respectively, while 
irradiation (with 2, 4, and 6 Gy) after eugenol treatment decreased the survival of cells to 86.4 ± 5.2%, 
74.5 ± 4.4%, and 49.3 ± 4.3%, respectively. These results showed that the proliferation inhibition 
ability of the combination of eugenol and radiation could potentially allow the reduction of 
radiotherapy doses and side effects. 
Figure 2. Effect of eugenol on se sitivity of HeLa c lls to cisplatin. HeLa cells were treated, in triplicate,
with diff rent concentrations (0–2.5 µM) of cisplatin alone or in c mbination with eugenol (350 µM)
for 24 h. The survival of cells, estimated by CCK-8, was expressed as a percentage relative to th t of
cells treated with medium only (without cisplatin or eugenol). Data represent mean ± SD. Significant
difference was analyzed by one-way ANOVA test, where *** p < 0.001 compared to cells not treated
with eugenol.
2.3. Effect of Eugenol on Sensitivity of HeLa Cells to radiation
The use of radiotherapy for cancer treatment has many adverse effects on adjacent normal cells.
The synergistic effect between radiation and natural products such as eugenol is interesting because
this might lead to the use of lower radiation doses resulting in fewer side effects. The effect of eugenol
treatment (350 µM) for 6 h and then irradiation with (0, 2, 4, and 6 Gy) X-rays on HeLa cell proliferation
is shown in Figure 3. The survival of cells after 24 h is expressed as a percentage relative to that of
non-irradiated cells treated with medium only. The results showed that eugenol significantly increased
the sensitivity of HeLa cells to irradiation at 4 Gy (p < 0.05) and 6 Gy (p < 0.01), while it failed to
increase the sensitivity of HeLa cells at 2 Gy irradiation. The survival of cells irradiated with only 2, 4,
and 6 Gy was 93.1 ± 5.6%, 89.3 ± 4.7% and 70.2 ± 5.1%, respectively, while irradiation (with 2, 4, and
6 Gy) after eugenol treatment decreased the survival of cells to 86.4 ± 5.2%, 74.5 ± 4.4%, and 49.3 ±
4.3%, respectively. These results showed that the proliferation inhibition ability of the combination of
eugenol and radiation could potentially allow the reduction of radiotherapy doses and side effects.
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Figure 3. Effect of eugenol on sensitivity of HeLa cells to radiation. HeLa cells were treated, in 
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2.4. Effect of Eugenol on Cell Signaling of HeLa Cells
2.4.1. Effect of Eugenol on Caspase-3 Activity in HeLa Cells
Caspases are a family of proteases that trigger apoptosis. During the early stages of apoptosis,
caspase-3 is activated and then it mediates the cleavage and activation of many key proteins involved
in the apoptosis cascade. The effect of treatment with medium alone or eugenol (350 µM)-containing
medium for 6, 12, or 24 h on caspase-3 activity is shown in Figure 4A. The results showed that eugenol
significantly increased caspase-3 activity in HeLa cells lysates in a time-dependent manner when
compared to cells treated with medium only.
2.4.2. Effect of Eugenol on Bax, Bcl-2, and Cox-2 Gene Expression in HeLa Cells
To analyze molecular targets of eugenol in HeLa cells, Bax, Bcl-2, and Cox-2 gene expression was
assessed after treating HeLa cells with medium or eugenol (350 µM)-containing medium for 12 or 24 h.
β-actin was used as the internal control. To confirm apoptosis induction by eugenol in HeLa cells and
explore the apoptotic pathway that eugenol activates, the levels of expression of different pro- and
anti-apoptotic genes such as Bax and Bcl-2 were assessed. As shown in Figure 4B, untreated HeLa cells
showed a relatively high expression of Bcl-2 which decreased after treatment with eugenol for 12 and
24 h. The expression of Bax, which is a pro-apoptotic gene, was increased following eugenol treatment.
From the results, a time-dependent increase in the Bax/Bcl-2 ratio after 12 and 24 h of eugenol treatment
was noticed, suggesting that eugenol activates apoptosis through the mitochondrial pathway.
Additionally, the effect of eugenol treatment on the expression of Cox-2 gene was investigated.
The results showed that the expression of Cox-2 gene was significantly decreased over time by eugenol
treatment. This showed that eugenol inhibited the proliferation of HeLa cells.
Taken together, these results indicated that Bcl-2, Bax, and Cox-2 gene expression was affected
by eugenol.
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2.4.3. Effect of Eugenol on Cytochrome c (Cyt-c), Caspase-3, Caspase-9, and Interleukin-1 Beta (IL-1β)
Protein Expression in HeLa Cells
Representative immunoblots of protein (Cyt-c, caspase-3, caspase-9, and IL-1β) expression in
HeLa cells treated with medium or eugenol (350 µM)-containing medium for 12 or 24 h are shown in
Figure 4C. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the internal control.
The results showed that eugenol increased the expression of all apoptotic proteins (Cyt-c, caspase-3,
and caspase-9) in a time-dependent manner, suggesting eugenol-dependent induction of apoptosis via
the mitochondrial pathway. Eugenol treatment significantly downregulated the (IL-1β) protein level
in a time-dependent manner to nearly undetectable levels after 24 h.Molecules 2019, 24, x FOR 6 of 14 
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3. Discussion
Many of the currently established cancer therapies are faci g problems due to the many side
effects as well as the development of resistance [33,34]. To overcome these problems, one approach
is combination therapy with agents acting on different signaling pathways as this results in higher
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effectiveness, less side effects and toxicity, and higher survival rates [35,36]. Recent studies focused
on dietary compounds such as genistein, eugenol, sulforaphane, curcumin, gallate, and resveratrol
as promising agents due to their antiproliferative or cytotoxic activity [19,37–40]. When combined
with these agents, traditional cancer therapies show a higher anticancer activity by synergism and
so lower doses can be used, having the advantage of reducing systemic toxicity originated by
chemotherapies or radiotherapies. Eugenol (4-allyl-2-methoxyphenol) is present in different spices
such as bay, cinnamon, and clove leaves as a main component of their essential oils [19]. Recently,
due to its antioxidant, anti-inflammatory, and anticancer abilities, eugenol has been examined for
different biological activities [7,41,42]. Previously, we described the great safety of eugenol and
the in vivo modulation of inducible nitric oxide synthase (iNOS) pathway by eugenol in carbon
tetrachloride-induced liver injury and showed its downregulation effect on the expression of tumor
necrosis factor (TNF)-α, interleukin-6 (IL-6), iNOS, and NF-κB [43]. Furthermore, authors are
now investigating the effect of different concentrations of eugenol on the characteristics of adipose
tissue-derived mesenchymal stem cells regarding their viability and migration abilities in vitro and the
impact of this effect on their hepatic antifibrotic activity in vivo, obtaining highly promising results
even at low concentrations of eugenol pre-treatment, but data have not been published yet.
In our study, eugenol treatment produced a significant dose-dependent and time-dependent
antiproliferative activity against HeLa cells, confirmed by viability assays and LDH release, which
is in accordance with other studies showing similar eugenol effects on different human cancer
cells [18,20,44–46]. Moreover, we show here that eugenol significantly increases the sensitivity of HeLa
cells to cisplatin at all cisplatin concentrations used in this study. Also, eugenol significantly increased
the sensitivity of HeLa cells to radiation (4 and 6 Gy). These results of eugenol-induced chemo- and
radio-sensitization were found in different cancer cell lines by many signaling pathways [47,48].
Our experiments provide a well-controlled baseline on which the following detailed analysis of
the potential effects of eugenol were conducted, identifying caspase-3, caspase-9, Bcl-2, and cytochrome
release as well as effects on mediators of inflammation (Bax, Cox-2, and IL-1β) as key targets of
eugenol action.
Moreover, lowering the radiation or chemotherapy doses depends on a synergistic effect between
these measures and eugenol. Co-administration of eugenol could minimize the adverse effects
of chemotherapy or radiation by lowering the applied doses. More experiments are planned to
check several combinations using Chou-Talalay method and study in detail the possible molecular
mechanisms for such combinatorial effects of eugenol.
Apoptosis or programmed cell death is an ordered process with cascade activation of many
proteins leading to cell death [49]. The inability to induce apoptosis may lead to the induction of
mutations which may be followed by carcinogenesis. However, and more importantly, the observed
cytotoxicity, indicated by LDH release which is induced by necrosis or late apoptosis, is an important
aspect for finding therapeutic drugs to treat cancer [50,51]. In order to investigate the apoptotic
pathway induced by eugenol toward HeLa cells, caspase-3 activity was assessed. Caspase-3 initiates
programmed cell death by acting on different proteins which lead to apoptotic, morphological, and
biological changes [52]. Our results show that eugenol significantly increases caspase-3 activity in
HeLa cell lysates in a time-dependent manner. These results are in accordance with the results of
previous studies on other cancer cells [52–54].
Eugenol triggered the cleavage of caspase-3, with a significant increase in its active forms
confirming apoptosis induction. To confirm that eugenol triggers apoptosis through the mitochondrial
pathway, we assessed the levels of caspase-9 that showed a significant increase with time in the
caspase-9 active form. Together, these results show that eugenol induces apoptosis in HeLa cells
through the internal mitochondrial pathway by the activation of caspase-9 and caspase-3.
Bcl-2 is an anti-apoptotic gene and has been involved in many cancers such as melanoma, breast,
lung, and liver carcinomas. It is also believed to have a role in cancer treatment resistance [55,56].
Hence, a search for promising cytotoxic agents capable of reducing Bcl-2 gene expression is necessary.
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The present results of eugenol effects on Bcl-2 gene expression in HeLa cells confirmed a significant
reduction in gene expression. Therefore, eugenol could induce and promote the antitumor activity of
common chemotherapeutic agents and radiation. Cox-2 gene, which is involved in the production
of prostaglandins, is known to have a role in inflammation and its high level has been associated
with many cancers [57,58]. Cox-2 mRNA expression was highly increased in many cancer cells and
this overexpression was found to be one of the causes of apoptosis resistance [26,59], so Cox-2 is
considered as a target for chemopreventive agents. This study investigated the effect of eugenol on
the expression of this cancer-related gene to explore its antiproliferative activity on HeLa cells. The
expression of Cox-2 gene in this study showed a significant decrease over time by eugenol treatment.
This confirms that eugenol, in part, inhibits the proliferation of HeLa cells by targeting Cox-2 gene in
cancer treatment strategies.
IL-1β, a member of the interleukin-1 cytokine family, is a central inflammatory mediator. It has a
role in many cellular processes such as immune response induction, prostaglandin synthesis and release,
cellular division, and apoptosis. IL-1β became an important therapeutic target in different inflammatory
diseases, immunity disorders, Alzheimer’s disease, and various tumors [60,61]. Accordingly, IL-1β
protein level was analyzed in this study in HeLa cells which showed that eugenol treatment significantly
downregulated IL-1β protein expression in a time-dependent manner. With regards to these results
of the pro-inflammatory cytokine (IL-1β) protein expression, which has a role in cellular division,
the antiproliferative effect of eugenol was, in part, attributed to its anti-inflammatory activity with
downregulation of this cancer-related protein.
4. Materials and Methods
4.1. Chemicals, Reagents, and Antibodies
Dulbecco’s Modified Eagle’s Medium (DMEM), L-glutamine, phosphate-buffered saline (PBS,
pH = 7.4), eugenol (>99% pure; molecular weight, 164.20), cisplatin, deoxyribonuclease I (DNase
I), and Tween 20 were obtained from Sigma-Aldrich, Inc (St Louis, MO, USA). A protease inhibitor
cocktail was purchased from Roche (Mannheim, Germany). Fetal bovine serum (FBS) was purchased
from Biosolutions International (Melbourne, Australia), while penicillin-streptomycin mixture and
PureLink™ RNA Mini Kit were obtained from Invitrogen (Grand Island, NY, USA). The cell counting
kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies (Dojindo Co., Kumamoto, Japan).
A lactate dehydrogenase (LDH) cytotoxicity assay kit was obtained from Cayman Chemical (Ann
Arbor, MI, USA) and a caspase-3 colorimetric activity assay kit was obtained from Millipore (Kankakee,
IL, USA). The ReverTra Ace qPCR RT Kit was purchased from Toyobo Co., Ltd. (Osaka, Japan) and a
Taq DNA polymerase kit was obtained from QIAGEN (Hilden, Germany). p-Nitroanilide (pNA) and
the primary antibodies against Cyt-c, IL-1β, caspase-3, caspase-9, and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) were obtained from Santa Cruz (CA, USA), while the secondary antibodies
conjugated with horseradish peroxidase were purchased from Life Technologies Japan (Tokyo, Japan).
4.2. Cell Culture and Reagents
HeLa cells, obtained from the American Type Culture Collection (ATCC: CCL-2, Manassas,
VA, USA), were maintained in fresh DMEM supplemented with 10% FBS, l-glutamine (10 g/L),
and penicillin-streptomycin mixture (10 g/L). Cells were cultured at 37 ◦C in a 5% CO2 humidified
incubator. Eugenol was kept at room temperature and diluted with the culture medium to the required
concentrations immediately before use for the treatment of HeLa cells.
4.3. Cell Viability Assay
Cell counting kit-8 (CCK-8) was used to quantitatively evaluate cell proliferation. Briefly, the cells
were seeded in triplicate at a density of 5 × 103 cells per well in 96-well plates and allowed to grow in
fresh DMEM medium for 24 h. The cells were then washed with PBS and the medium was changed to
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fresh DMEM containing different concentrations (0–1000 µM) of eugenol. After the specified time of
incubation, the cells were washed again with PBS, then 100 µL of DMEM medium with 10% WST-8
(2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium) solution was
added to the wells, and the plate was incubated for 2 h. Then, the absorbance of the wells at 450
nm was measured using the HTS Multi-Mode Microplate Reader (BioTek Instruments, Winooski, VT,
USA). The absorbance is proportional to the number of viable cells in the medium. Cell proliferation
at different time points was expressed as a percentage relative to that of cells treated with medium
without eugenol.
4.4. Cytotoxicity Assay
LDH enzyme leakage into the culture medium is a well-known indicator of cell membrane injury
and cell cytotoxicity. It was measured using the LDH cytotoxicity assay kit. Briefly, cells (5 × 103 cells
per well) were seeded in triplicate in 96-well plates and incubated overnight in fresh DMEM medium
before changing the medium to a fresh one containing different concentrations (0–1000 µM) of eugenol.
After 24 h, 100 µL of medium from each well was carefully transferred to new plates and 100 µL of
LDH reaction solution, prepared according to the manufacturer’s instructions, was added to each well.
Plates were gently shaken at 37 ◦C for 30 min, then, absorbance was measured at 490 nm. LDH release
(cytotoxicity) was expressed as a percent relative to that of 10% Triton X-100-treated cells.
4.5. Chemotherapy Sensitivity Assay
To check if eugenol affected the sensitivity of HeLa cells to cisplatin, cell survival was examined
after treating the cells with cisplatin alone or in combination with eugenol. Cells were seeded in
triplicate at a density of 5 × 103 cells per well in 96-well plates and incubated overnight in fresh DMEM
medium. Then medium was changed to a fresh one containing different concentrations (0–2.5 µM)
of cisplatin alone or in combination with eugenol (350 µM). After 24 h, cell survival was determined
by CCK-8 as described above and was expressed as a percentage relative to that of cells treated with
medium only (without cisplatin or eugenol).
4.6. Radiotherapy Sensitivity Assay
To examine if eugenol increased HeLa cell sensitivity to radiation, cells (5 × 103 cells per well)
were seeded in triplicate in 96-well plates and allowed to grow in fresh DMEM medium for 24 h. They
were treated with eugenol (350 µM)-containing medium for 6 h. Then, cells were irradiated with (0, 2,
4, and 6 Gy) X-rays generated with an X-ray apparatus (Hitachi Medico Technology Co., Kashiwa,
Japan) operating at 150 kV and 120 mA and the medium was replaced with fresh medium. After 24 h,
cell survival was determined by CCK-8 as described before and was expressed as a percentage relative
to that of non-radiated cells treated with medium only (without eugenol).
4.7. Caspase-3 Activity Analysis
The caspase-3 colorimetric activity assay kit was used for the detection of caspase-3 activity.
Briefly, cells were seeded in 25 cm2 tissue culture flasks and incubated overnight before being treated
with medium or eugenol (350 µM)-containing medium for 6, 12, or 24 h. Then, cell lysates were
prepared using the lysis buffer for caspase-3 activity assay according to the manufacturer’s instructions.
Lysates were transferred to 96-well plates. The concentration of para-nitro aniline (pNA) released
from the substrate, which was added and incubated for 1 h at 37 ◦C, by caspase-3 was calculated
from the absorbance measured at 405 nm and from a calibration curve prepared with known pNA
concentrations. Data were obtained from three independent experiments.
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4.8. Expression Analysis of Bax, Bcl-2, and Cox-2 Genes by Reverse Transcription-PCR
Total RNA was extracted from untreated and eugenol-treated cells using the PureLink™ RNA
Mini Kit according to the manufacturer’s instructions. The amount of RNA extracted was measured
spectrophotometrically on NanoDrop 1000 (Thermo Scientific, Waltham, MA, USA). Aliquots of
RNA were treated with 0.1 U/µL DNase I at room temperature for 15 min to remove genomic DNA.
cDNAs were synthesized using 0.5 µg DNase I-treated RNA by using the ReverTra Ace qPCR RT Kit
according to the manufacturer’s instruction. The resulting cDNA was subjected to PCR using the
Taq DNA polymerase kit. PCR was performed with initial denaturation for 70 s at 95 ◦C, followed
by 30 amplification cycles (denaturing for 45 s at 93 ◦C, annealing for 45 s at the specific annealing
temperature, and elongation for 40 s at 72 ◦C) with final extension for 100 s at 72 ◦C, in a 25 µL reaction
mixture according to the manufacturer’s instruction using the thermal cycler (Applied Biosystems,
Gene Amp PCR System 2700). Primer sequences used and annealing temperatures are mentioned in
Table 1. The β-actin primer was used as the internal control. Amplified products were separated on 2%
agarose gels containing 0.1 µg/mL ethidium bromide and visualized by LAS-3000 (Fujifilm, Tokyo,
Japan) and Multi-Gauge v3.0 software (Fujifilm, Tokyo, Japan).
Table 1. Primers used in reverse transcription-PCR.
Primer Sequence of the Primer Annealing Temperature Size (bp)
Bax
Forward: 5′-GTTTCATCCAGGATCGAGCAG-3′
53 ◦C 487Reverse: 5′-CATCTTCTTCCAGATGGTGA-3′
Bcl-2
Forward: 5′-CCTGTGGATGACTGAGTACC-3′
53 ◦C 127Reverse: 5′-GAGACAGCCAGGAGAAATCA-3′
Cox-2
Forward: 5′-ATACCAAAACCGCATTGCCG-3′
57 ◦C 305Reverse: 5′-TCTAACTCCGCAGCCATTTC-3′
β-Actin Forward: 5
′-CGGGACCTGACTGACTAC-3′
56 ◦C 252Reverse: 5′-GAAGGAAGGCTGGAAGAG-3′
4.9. Western Blot Assay of Cyt-c, Caspase-3, Caspase-9, and IL-1β Protein Expression
Protein expression levels were assessed by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and immunoblotting. HeLa cells were cultured in six-well plates and
treated with medium or eugenol (350 µM)-containing medium for 12 or 24 h as described above.
Cells were then collected, washed, and lysed with RIPA lysis buffer containing 150 mM NaCl, 50 mM
Tris-Cl, pH 7.5, 0.1% SDS, 0.5% sodium deoxycholate, 2 mM phenylmethylsulfonyl fluoride, and 1%
Nonidet P-40, supplemented with the protease inhibitor cocktail. Cell lysates containing 50 µg of
protein were separated by SDS-PAGE (15% acrylamide) and transferred onto polyvinylidene fluoride
membranes (Millipore) which were blocked with 5% skimmed milk for 30 min at room temperature
and washed with PBS containing 0.3% Tween 20 and then incubated overnight at 4 ◦C with the
primary antibodies (1:500 dilution in PBS) for Cyt-c, IL-1β, caspase-3, and caspase-9. Bound primary
antibodies were detected by incubating the membranes for 1 h with the respective secondary antibodies
conjugated with horseradish peroxidase. Immunoreactive proteins were detected using an enhanced
chemiluminescence system (Life Technologies Japan) according to the manufacturer’s instructions
and visualized using a luminescent image analyzer (LAS-4000, Fujifilm Co., Tokyo, Japan). Each
immunoblotting was repeated three times. GAPDH (1:1000 dilution) was used as the internal control
to ensure equal loading and blotting. The Bio-Rad Trans-Blot SD Cell apparatus (Bio-Rad, Hercules,
CA) was used in electrophoresis and electroblotting.
4.10. Statistical Analysis
All results were expressed as mean ± standard deviation. Statistical comparison was conducted
using Student’s t-test after one-way analysis of variance (ANOVA) using GraphPad Prism 5 statistical
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software (GraphPad, La Jolla, CA, USA) and Excel software (Microsoft, Redwood, WA, USA). The
results were considered to be significant when the probability values (p) were less than 0.05.
5. Conclusions
From this study, it is concluded that Bcl-2, Bax, Cox-2, and IL-1β expressions in HeLa cells are
affected by eugenol. Eugenol may target IL-1β, which then blocks the downstream targets Bcl-2 and
Cox-2. Authors currently examine, but this is not completed yet, the eugenol molecular effects on other
normal and cancer cell lines and these ongoing studies confirm in their trends the effects reported here.
Thus, this study investigated the molecular mechanism of eugenol underlying its anticancer effect on
human cervical cancer HeLa cells and their sensitivity increase to common therapies, demonstrating
the ability of eugenol as a promising anti-inflammatory, anticarcinogenic, cytotoxic, and chemo- and
radio-sensitizing agent acting through various signaling pathways.
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